Versatile strategy for controlling the specificity and activity of engineered T cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 4, 2016, Pages E450-E458

  Ma, Jennifer S Y ^a   Kim, Ji Young ^a   Kazane, Stephanie A ^a,e   Choi, Sei Hyun ^b   Yun, Hwa Young ^b,f   Kim, Min Soo ^a,g   Rodgers, David T ^a   Pugh, Holly M ^a   Singer, Oded ^a   Sun, Sophie B ^a   Fonslow, Bryan R ^b,c   Kochenderfer, James N ^d   Wright, Timothy M ^a   Schultz, Peter G ^a,b   Young, Travis S ^a   Kim, Chan Hyuk ^a   Cao, Yu ^b  

^a California Institute for Biomedical Research   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c MDS SCIEX   (Canada)

^d NATIONAL CANCER INSTITUTE   (United States)

^e PFIZER INC   (United States)

^f Pusan National University   (South Korea)

^g SORRENTO THERAPEUTICS   (United States)

Author keywords

B cell aplasia; Cancer immunotherapy; Chimeric antigen receptor T cell; Cytokine release syndrome; Noncanonical amino acids

Indexed keywords

AMINO ACID; CD19 ANTIBODY; CD19 ANTIGEN; CD22 ANTIBODY; CD22 ANTIGEN; CELL ANTIBODY; CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; FLUORESCEIN ISOTHIOCYANATE; UNCLASSIFIED DRUG; 4-AZIDOPHENYLALANINE; AZIDE; CD22 PROTEIN, HUMAN; CTL019 CHIMERIC ANTIGEN RECEPTOR; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; PHENYLALANINE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APLASIA; ARTICLE; B CELL APLASIA; B CELL LEUKEMIA; CANCER CELL; CELL ENGINEERING; CELL INTERACTION; CELL SPECIFICITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; FEMALE; GEOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; SOLID TUMOR; STOICHIOMETRY; T LYMPHOCYTE; TUMOR XENOGRAFT; ADOPTIVE IMMUNOTHERAPY; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANIMAL; B LYMPHOCYTE; C57BL MOUSE; DRUG SCREENING; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; LENTIVIRINAE; LEUKEMIA, B-CELL; LYMPHOCYTE ACTIVATION; LYMPHOPENIA; MOLECULAR MODEL; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROCEDURES; PROTEIN CONFORMATION; PROTEIN ENGINEERING; SCID MOUSE; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD19; ANTIGENS, NEOPLASM; AZIDES; B-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LENTIVIRUS; LEUKEMIA, B-CELL; LYMPHOCYTE ACTIVATION; LYMPHOPENIA; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; MODELS, MOLECULAR; PHENYLALANINE; PROTEIN CONFORMATION; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SIALIC ACID BINDING IG-LIKE LECTIN 2; SINGLE-CHAIN ANTIBODIES; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955502256     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1524193113     Document Type: Article

References (50)

1. Grupp SA, et al. (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368(16):1509-1518.
2. Davila ML, et al. (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6(224):224ra25.
3. Barrett DM, Singh N, Porter DL, Grupp SA, June CH (2014) Chimeric antigen receptor therapy for cancer. Annu Rev Med 65:333-347.
4. Maude SL, Barrett D, Teachey DT, Grupp SA (2014) Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 20(2):119-122.
5. Tey SK (2014) Adoptive T-cell therapy: Adverse events and safety switches. Clin Transl Immunology 3(6):e17.
6. Kochenderfer JN, et al. (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigenreceptor-transduced T cells. Blood 119(12):2709-2720.
7. Kochenderfer JN, et al. (2010) Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116(20):4099-4102.
8. Morgan RA, et al. (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18(4):843-851.
9. Lamers CH, et al. (2013) Treatment of metastatic renal cell carcinoma with CAIX CARengineered T cells: Clinical evaluation and management of on-target toxicity. Mol Ther 21(4):904-912.
10. Parkhurst MR, et al. (2011) T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19(3):620-626.
11. Morgan RA, et al. (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36(2):133-151.
12. Kenderian SS, et al. (2015) CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 29(8): 1637-1647.
13. Di Stasi A, et al. (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365(18):1673-1683.
14. Wilkie S, et al. (2012) Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol 32(5):1059-1070.
15. Fedorov VD, Themeli M, Sadelain M (2013) PD-1-and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med 5(215):215ra172.
16. Wu CY, Roybal KT, Puchner EM, Onuffer J, Lim WA (2015) Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 350(6258): aab4077.
17. Kudo K, et al. (2014) T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res 74(1):93-103.
18. Tamada K, et al. (2012) Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res 18(23):6436-6445.
19. Urbanska K, et al. (2012) A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res 72(7):1844-1852.
20. Kim MS, et al. (2015) Redirection of genetically engineered CAR-T cells using bifunctional small molecules. J Am Chem Soc 137(8):2832-2835.
21. Hudecek M, et al. (2013) Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 19(12):3153-3164.
22. Guest RD, et al. (2005) The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother 28(3):203-211.
23. van Dam GM, et al. (2011) Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-a targeting: First in-human results. Nat Med 17(10): 1315-1319.
24. Herron JN, et al. (1994) High resolution structures of the 4-4-20 Fab-fluorescein complex in two solvent systems: Effects of solvent on structure and antigen-binding affinity. Biophys J 67(6):2167-2183.
25. Jung S, Plückthun A (1997) Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting. Protein Eng 10(8):959-966.
26. Boder ET, Midelfort KS, Wittrup KD (2000) Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci USA 97(20): 10701-10705.
27. Vaughan TJ, et al. (1996) Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 14(3):309-314.
28. Maus MV, et al. (2013) T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 1(1):26-31.
29. Kalos M, et al. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73.
30. Maude SL, et al. (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507-1517.
31. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725-733.
32. Spiegelberg HL, Weigle WO (1965) The catabolism of homologous and heterologous 7s gamma globulin fragments. J Exp Med 121:323-338.
33. Kim CH, Axup JY, Schultz PG (2013) Protein conjugation with genetically encoded unnatural amino acids. Curr Opin Chem Biol 17(3):412-419.
34. Axup JY, et al. (2012) Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci USA 109(40):16101-16106.
35. Kim CH, et al. (2012) Synthesis of bispecific antibodies using genetically encoded unnatural amino acids. J Am Chem Soc 134(24):9918-9921.
36. Cao Y, et al. (2015) Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers. Angew Chem Int Ed Engl 54(24):7022-7027.
37. Kim CH, et al. (2013) Bispecific small molecule-antibody conjugate targeting prostate cancer. Proc Natl Acad Sci USA 110(44):17796-17801.
38. Long AH, et al. (2015) 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21(6):581-590.
39. Haso W, et al. (2013) Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121(7):1165-1174.
40. Stärck L, Scholz C, Dörken B, Daniel PT (2005) Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces Bcl-xL and c-FLIP(short) via phosphatidylinositol 3-kinase and AKT/protein kinase B. Eur J Immunol 35(4):1257-1266.
41. Kalaitsidou M, Kueberuwa G, Schütt A, Gilham DE (2015) CAR T-cell therapy: Toxicity and the relevance of preclinical models. Immunotherapy 7(5):487-497.
42. Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA (2010) Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116(19):3875-3886.
43. Davila ML, Kloss CC, Gunset G, Sadelain M (2013) CD19 CAR-targeted T cells induce long-term remission and B Cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One 8(4):e61338.
44. Hudecek M, et al. (2015) The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res 3(2): 125-135.
45. Qin H, et al. (2015) Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood 126(5):629-639.
46. Bluemel C, et al. (2010) Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother 59(8):1197-1209.
47. Long AH, Haso WM, Orentas RJ (2013) Lessons learned from a highly-active CD22-specific chimeric antigen receptor. OncoImmunology 2(4):e23621.
48. Wang R, Natarajan K, Margulies DH (2009) Structural basis of the CD8 alpha beta/ MHC class I interaction: Focused recognition orients CD8 beta to a T cell proximal position. J Immunol 183(4):2554-2564.
49. Rodgers D, et al. (2015) Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci USA 113:E459-E468.
50. Wang QS, et al. (2015) Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther 23(1):184-191.